On January 6, 2026 NanOlogy, LLC, a clinical-stage oncology company, reported the appointment of John M. Goldberg, MD as fractional Chief Medical Officer (CMO) to advance development of its Large Surface Area Microparticle (LSAM) drug portfolio including its development program targeting Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brain cancer with limited treatment options.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
John is a graduate of the University of Massachusetts Chan Medical School and is board-certified in Pediatric Hematology/Oncology, with more than 20 years of experience in all phases of drug development, from early research through late-phase clinical trials. His most recent roles as CMO included positions at Rafael Holding, Inc., a healthcare investment, family office, and biotechnology company, and at Oncorus, Inc., a biopharmaceutical company developing an intratumorally delivered viral immunotherapy for cancer. Earlier in his career, John served as Senior Medical Director at H3 Biomedicine Inc. (a research subsidiary of Eisai) and Medical Director at Agenus, Inc., and was also a Lecturer part-time at Harvard Medical School and Associate Professor at the University of Miami Miller School of Medicine.
"As we progress our DIPG program toward initiating a clinical trial in late 2026 and advance our clinical-stage investigational drugs into late-phase clinical trials, John will play a critical role in our development strategy and execution," said David Arthur, CEO of Nanology. "John’s broad expertise across both drug development and business strategy will strengthen our ability to rapidly advance these programs."
"I am impressed by NanOlogy’s progress and believe my experience, including development of intratumoral therapies, positions me well to contribute to NanOlogy’s future success," said John Goldberg, MD. "My initial priorities are to advance the DIPG program and select the best clinical pathway for our adult solid tumor investigational drugs. I am looking forward to our progress and the benefit it may hold for cancer patients."
(Press release, NanOlogy, JAN 6, 2026, View Source;utm_medium=rss&utm_campaign=nanology-appoints-john-m-goldberg-md-as-chief-medical-officer-to-further-its-preclinical-clinical-large-surface-area-microparticle-investigational-drug-portfolio [SID1234661756])